Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Trading Update

25th Mar 2009 07:00

RNS Number : 4157P

Immunodiagnostic Systems Hldgs PLC

25 March 2009

Immunodiagnostic Systems Holdings PLC

("IDS" or the "Group")

Trading Update

IDS, a leading producer of diagnostic testing kits, announces that revenue for the year ending 31 March 2009 is expected to be circa 43% ahead of last year's numbers (y/e 31 March 2008: £18.66m). Revenue on a continuing operations basis is expected to increase by circa 47%, with revenue from the divested haematology business for the 9 month period to 31 December 2008 amounting to £2.45m (y/e 31 March 2008: £2.19m).

Costs remain under control and trading in all of the Group's main territories has increased year on year as well as across the Group's key products. Sales into the USA, France and Germany have seen significant growth this year.

Profits before tax prior to a net exceptional gain for the year ending 31 March 2009 are expected to be in line with expectations.

Prospects for the new financial year look good, as we build upon the launch of our new IDSiSYS automated analyzer as announced on 2 March 2009. We will provide a further update on progress for the IDSiSYS and the development of further analytes when the Group announces its year end results in June 2009.

Enquiries:

IDS	Tel: 0191 519 0660
Roger Duggan, CEO
Paul Hailes, Finance Director	www.idsplc.com

Parkgreen Communications Ltd	Tel: 020 7933 8787
Paul McManus	Mob: 07980 541 893
	[email protected]

Oriel Securities Ltd	Nominated Advisor and joint broker
Richard Crawley or Gareth Price	Tel: 020 7710 7600

Teathers	Joint broker
Shaun Dobson	Tel: 020 7426 9582

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCILFVDVVISFIA

Related Shares:

FTSE 100 Latest

Value8,463.46

Change46.12